SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNPRNewsWire • 11/04/22
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022GlobeNewsWire • 10/25/22
Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson PortfolioSeeking Alpha • 08/19/22
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022GlobeNewsWire • 07/25/22
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022GlobeNewsWire • 05/02/22
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 04/13/22
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial GuidanceGlobeNewsWire • 04/04/22
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain ComplianceGlobeNewsWire • 03/17/22
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22